NEW YORK (GenomeWeb News) – Cellular Dynamics International today said that it has signed a deal to supply the Nestlé Institute of Health Sciences with its iCell and MyCell product lines.

The iCell portfolio includes cardiomyocytes, neurons, hepatocytes, endothelial cells, and other cell types in development, while the MyCell line includes cell products manufactured from donor samples using iPSC technology to make stem cells or differentiated cells from any individual.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.